Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/1984
Título : Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Autor : Capdevila, Jaume
Sevilla, Isabel
Alonso, Vicente
Antón Aparicio, Luís
Jiménez Fonseca, Paula
Grande, Enrique
Reina, Juan José
Manzano, José Luís
Alonso Lájara, Juan Domingo
Barriuso, Jorge
Castellano, Daniel
Medina, Javier
López, Carlos
Segura, Ángel
Carrera, Sergio
Crespo, Guillermo
Fuster, José
Munarriz, Javier
García Alfonso, Pilar
Filiación: [Capdevila,J] Medical Oncology Department, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Spain. [Sevilla,I] Medical Oncology Department, Virgen de la Victoria University Hospital, Málaga, Spain. [Alonso,V] Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain. [Antón Aparicio,L] Medical Oncology Department, University Hospital Complex, As Xubias, A Coruña, Spain. [Jiménez Fonseca,P] Medical Oncology Department, Asturias Central University Hospital, Oviedo, Spain. [Grande,E] Medical Oncology Department, Ramón y Cajal University Hospita, Madrid, Spain. [Reina,JJ] Medical Oncology Department, Virgen Macarena University Hospital, Sevilla, Spain. [Manzano,JL] Medical Oncology Department, Catalan Oncology Institute (ICO-Badalona), Germans Trias i Pujol University Hospital, Barcelona, Spain. [Alonso Lájara,JD] Medical Oncology Department, Virgen de la Arrixaca University Hospital, Murcia, Spain. [Barriuso,J] Medical Oncology Department, La Paz University Hospital, Madrid, Spain. [Castellano,D] Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain. [Medina,J] Medical Oncology Department, Toledo Hospital Complex, Toledo, Spain. [López,C] Medical Oncology Department, La Fe University Hospital, Valencia, Spain. [Carrera,S] Medical Oncology Department, Cruces University Hospital, Vizcaya, Spain. [Crespo,G] Medical Oncology Department, Burgos University Hospital, Burgos, Spain. [Fuster,J] Medical Oncology Department, Son Dureta University Hospital, Palma de Mallorca, Spain. [Munarriz,J] Medical Oncology Department, Castellón Provincial Hospital Consortium, Castellón de la Plana, Spain. [García Alfonso,P] Medical Oncology Department, Gregorio Marañon Hospital, Madrid, Spain.
Palabras clave : Lanreotide
Neuroendocrine tumours
Sunitinib
Everolimus
Somatostatin analogues
Clinical practice
Cross-sectional analysis
Combination treatment
Tumores Neuroendocrinos
Péptidos Cíclicos
Estudios Prospectivos
Sirolimus
Somatostatina
Inhibidores de la Angiogénesis
MeSH: Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Growth Substances::Angiogenesis Modulating Agents::Angiogenesis Inhibitors
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Indoles
Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors
Medical Subject Headings::Check Tags::Male
Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Macrocyclic Compounds::Peptides, Cyclic
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Pyrroles
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies
Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Lactones::Macrolides::Sirolimus
Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Pancreatic Neoplasms::Carcinoma, Islet Cell::Somatostatinoma
Medical Subject Headings::Geographicals::Geographic Locations::Europe::Spain
Fecha de publicación : 4-Jul-2015
Editorial : BioMed Central
Cita Bibliográfica: Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015; 15:495
Abstract: BACKGROUND Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). Herein, we investigate the use of these treatment combinations in clinical practice. METHODS This retrospective cross-sectional analysis of patients with NETs treated with the SSA lanreotide and targeted therapies at 35 Spanish hospitals evaluated the efficacy and safety of lanreotide treatment combinations in clinical practice. The data of 159 treatment combinations with lanreotide in 133 patients was retrospectively collected. RESULTS Of the 133 patients, with a median age of 59.4 (16-83) years, 70 (52.6 %) patients were male, 64 (48.1 %) had pancreatic NET, 23 (17.3 %) had ECOG PS ≥2, 41 (30.8 %) had functioning tumours, 63 (47.7 %) underwent surgery of the primary tumour, 45 (33.8 %) had received prior chemotherapy, and 115 (86.5 %) had received prior SSAs. 115 patients received 1 lanreotide treatment combination and 18 patients received between 2 and 5 combinations. Lanreotide was mainly administered in combination with everolimus (73 combinations) or sunitinib (61 combinations). The probability of being progression-free was 78.5 % (6 months), 68.6 % (12 months) and 57.0 % (18 months) for patients who only received everolimus plus lanreotide (n = 57) and 89.3 % (6 months), 73.0 % (12 months), and 67.4 % (18 months) for patients who only received sunitinib and lanreotide (n = 50). In patients who only received everolimus plus lanreotide the median time-to-progression from the initiation of lanreotide combination treatment was 25.8 months (95 % CI, 11.3, 40.3) and it had not yet been reached among the subgroup of patients only receiving sunitinib plus lanreotide. The safety profile of the combination treatment was comparable to that of the targeted agent alone. CONCLUSIONS The combination of lanreotide and targeted therapies, mainly everolimus and sunitinib, is widely used in clinical practice without unexpected toxicities and suggests efficacy that should be explored in randomized prospective clinical trials.
Descripción : Journal Article;
URI: http://hdl.handle.net/10668/1984
Versión del editor : http://www.biomedcentral.com/1471-2407/15/495/abstract
DOI: 10.1186/s12885-015-1512-6
ISSN : 1471-2407 (Online)
Appears in Collections:01- Artículos - Hospital Virgen de la Victoria
01- Artículos - Hospital Virgen Macarena

Files in This Item:
File Description SizeFormat 
Capdevila_EvaluationEfficacySafety.pdfArtículo publicado1,12 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons